In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.

about

In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.

Item

http://www.wikidata.org/entity/Q41748682

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

In patients with myelodysplast ...... e, which diminishes over time.

@en

type

Item

label

In patients with myelodysplast ...... e, which diminishes over time.

@en

prefLabel

In patients with myelodysplast ...... e, which diminishes over time.

@en

P1476

In patients with myelodysplast ...... e, which diminishes over time.

@en

P2093

Andrea Kündgen

http://www.w3.org/2001/XMLSchema#string

Corinna Strupp

http://www.w3.org/2001/XMLSchema#string

Jennifer Schemenau

http://www.w3.org/2001/XMLSchema#string

Joerg Hasford

http://www.w3.org/2001/XMLSchema#string

Michael Lauseker

http://www.w3.org/2001/XMLSchema#string

P2860

A new look at the statistical model identification

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

Sex difference in myelodysplastic syndrome survival and balance in randomized clinical trials.

Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Reg

A prognostic score for patients with lower risk myelodysplastic syndrome.

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.

The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997.

Impact on survival of different treatments for myelodysplastic syndromes (MDS).

P304

687-693

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.13496

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

170

http://www.w3.org/2001/XMLSchema#string

P50

Ulrich Germing

Norbert Gattermann

P577

2015-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25960152

http://www.w3.org/2001/XMLSchema#string